|
Market Closed -
NYSE
16:00:02 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 83.85 USD | +3.10% |
|
-7.09% | +5.66% |
| 11-06 | CVS Health Insider Bought Shares Worth $2,001,315, According to a Recent SEC Filing | MT |
| 11-06 | Goldman Sachs Adjusts Price Target on CVS Health to $115 From $120 | MT |
| Market Cap | 107B 96.22B 87.94B 80.28B 151B 10,085B 156B 1,060B 423B 5,381B 403B 394B 16,988B | P/E 2026 * |
11.8x | P/E 2027 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise Value | 161B 145B 132B 121B 227B 15,160B 235B 1,593B 635B 8,089B 605B 592B 25,537B | EV / Sales 2026 * |
0.38x | EV / Sales 2027 * | 0.36x |
| Free-Float |
71.22% | Yield 2026 * |
3.18% | Yield 2027 * | 3.25% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| CVS | Delayed | |
CBOE
| CVS | Real-time | |
|
Tradegate
| CVS | Real-time | |
|
Xetra
| CVS | Delayed | |
|
Deutsche Boerse AG
| CVS | Delayed | |
|
Boerse Muenchen
| CVS | Real-time | |
|
Mexican S.E.
| CVS * | End-of-day quote | |
|
Börse Stuttgart
| CVS | Delayed | |
|
London S.E.
| 0HRS | Delayed | |
|
CBOE
| Real-time | ||
|
CBOE
| 0HRS | Real-time | |
|
Swiss Exchange
| CVS | Delayed | |
|
Santiago S.E.
| CVS | End-of-day quote | |
|
Santiago S.E.
| CVSCL | End-of-day quote | |
|
Borsa Italiana
| 1CVS | End-of-day quote | |
|
Lima
| CVSUS | End-of-day quote | |
|
Wiener Boerse
| CVS | End-of-day quote | |
|
Swiss Exchange
| CVS | Delayed |
Last Transcript: CVS Health Corporation
| 1 day | +3.10% | ||
| 1 week | -7.09% | ||
| Current month | -7.09% | ||
| 1 month | -4.66% | ||
| 3 months | -12.38% | ||
| 6 months | -4.02% | ||
| Current year | +5.66% |
| 1 week | 77.33 |  | 91.89 |
| 1 month | 77.33 | | 95.26 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/31/26 | Tax | Chief Financial Officer | -2,478 | 0.0002% | ||
| 5/31/26 | Tax | Chief Technology Officer | -7,618 | 0.0006% | ||
| 5/21/26 | Glenview Capital Management LLC
| Sell | Company | -748,462 | 0.0584% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.10% | -7.09% | +6.15% | +19.36% | 107B | |
| -2.46% | +4.61% | +3.86% | +112.34% | 103B | |
| -14.59% | -25.01% | +55.67% | +611.89% | 45.05B | |
| +1.18% | +9.80% | +10.16% | +108.42% | 32.96B | |
| +0.90% | +1.43% | +45.05% | +77.11% | 29.77B | |
| +0.35% | +1.51% | +42.41% | +92.38% | 28.12B | |
| -1.09% | +3.69% | +38.03% | +409.59% | 22.55B | |
| -0.37% | -2.93% | -19.48% | -17.94% | 20.12B | |
| -0.26% | -1.91% | -7.00% | +27.27% | 16.76B | |
| +1.96% | +0.39% | +102.63% | - | 13.96B | |
| Average | -1.13% | -1.69% | +27.75% | +160.05% | 42B | |
| Weighted average by Cap. | -1.22% | -2.51% | +19.56% | +145.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 423B 379B 346B 316B 596B 39,735B 615B 4,176B 1,665B 21,202B 1,587B 1,553B 66,932B | 431B 387B 353B 323B 608B 40,525B 627B 4,259B 1,698B 21,623B 1,618B 1,583B 68,263B |
| Net income | 9.02B 8.09B 7.4B 6.75B 12.72B 848B 13.12B 89.14B 35.55B 453B 33.87B 33.14B 1,429B | 9.39B 8.42B 7.69B 7.02B 13.23B 882B 13.65B 92.75B 36.98B 471B 35.23B 34.48B 1,486B |
| Net Debt | 53.99B 48.42B 44.26B 40.4B 76.11B 5,075B 78.51B 533B 213B 2,708B 203B 198B 8,549B | 49.56B 44.45B 40.62B 37.08B 69.87B 4,659B 72.07B 490B 195B 2,486B 186B 182B 7,847B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-06 | US$83.85 | +3.10% | 16,099,672 |
| 26-11-05 | US$81.33 | +1.71% | 19,930,575 |
| 26-11-04 | US$79.96 | -12.53% | 34,289,772 |
| 26-11-03 | US$91.41 | +3.28% | 19,630,048 |
| 26-11-02 | US$88.51 | -1.93% | 9,698,593 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
